AU2020334147A1 - Compositions and methods for neurological diseases - Google Patents

Compositions and methods for neurological diseases Download PDF

Info

Publication number
AU2020334147A1
AU2020334147A1 AU2020334147A AU2020334147A AU2020334147A1 AU 2020334147 A1 AU2020334147 A1 AU 2020334147A1 AU 2020334147 A AU2020334147 A AU 2020334147A AU 2020334147 A AU2020334147 A AU 2020334147A AU 2020334147 A1 AU2020334147 A1 AU 2020334147A1
Authority
AU
Australia
Prior art keywords
receptor
neuron
vector
pain
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020334147A
Other languages
English (en)
Inventor
Orion P. KEIFER Jr.
Anthony LAU Jr.
Stefanie MAKINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trames Bio Inc
Original Assignee
Trames Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trames Bio Inc filed Critical Trames Bio Inc
Publication of AU2020334147A1 publication Critical patent/AU2020334147A1/en
Assigned to TRAMES BIO, INC. reassignment TRAMES BIO, INC. Request for Assignment Assignors: Coda Biotherapeutics, Inc.
Priority to AU2026205301A priority Critical patent/AU2026205301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2020334147A 2019-08-21 2020-08-21 Compositions and methods for neurological diseases Abandoned AU2020334147A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026205301A AU2026205301A1 (en) 2019-08-21 2026-07-06 Compositions and methods for neurological diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889963P 2019-08-21 2019-08-21
US62/889,963 2019-08-21
PCT/US2020/047503 WO2021035179A1 (en) 2019-08-21 2020-08-21 Compositions and methods for neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026205301A Division AU2026205301A1 (en) 2019-08-21 2026-07-06 Compositions and methods for neurological diseases

Publications (1)

Publication Number Publication Date
AU2020334147A1 true AU2020334147A1 (en) 2022-03-31

Family

ID=72356519

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020334147A Abandoned AU2020334147A1 (en) 2019-08-21 2020-08-21 Compositions and methods for neurological diseases
AU2026205301A Pending AU2026205301A1 (en) 2019-08-21 2026-07-06 Compositions and methods for neurological diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026205301A Pending AU2026205301A1 (en) 2019-08-21 2026-07-06 Compositions and methods for neurological diseases

Country Status (7)

Country Link
US (1) US20220348635A1 (cg-RX-API-DMAC7.html)
EP (1) EP4017874A1 (cg-RX-API-DMAC7.html)
JP (2) JP7781052B2 (cg-RX-API-DMAC7.html)
CN (1) CN114746450A (cg-RX-API-DMAC7.html)
AU (2) AU2020334147A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151920A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021035179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
CN111556751B (zh) 2017-11-10 2024-07-12 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
US20250009906A1 (en) * 2021-11-19 2025-01-09 President And Fellows Of Harvard College Nociceptor-specific gene regulatory elements for the treatment of pain
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
EP4514831A4 (en) * 2022-04-27 2026-06-17 Hughes Howard Med Inst Chemogenetic receptors and their manufacturing and use processes
EP4702043A1 (en) * 2023-04-28 2026-03-04 Kriya Therapeutics, Inc. Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders
WO2025117698A1 (en) * 2023-12-01 2025-06-05 Massachusetts Institute Of Technology Ribozyme-enhanced rna trans-splicing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2003267174A1 (en) 2002-05-09 2003-11-11 Memory Pharmaceuticals Corporation Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
WO2004074245A2 (en) 2003-02-14 2004-09-02 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2009042723A1 (en) 2007-09-25 2009-04-02 California Institute Of Technology Transgenic mice expressing hypersensitive nicotinic receptors
JP5511144B2 (ja) 2008-02-12 2014-06-04 学校法人福岡大学 てんかんモデル非ヒト哺乳動物
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US11713470B2 (en) * 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
CN111556751B (zh) * 2017-11-10 2024-07-12 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
IL274702B2 (en) * 2017-11-27 2026-04-01 Coda Biotherapeutics Inc Compounds and methods for neurological diseases

Also Published As

Publication number Publication date
CN114746450A (zh) 2022-07-12
WO2021035179A1 (en) 2021-02-25
CA3151920A1 (en) 2021-02-25
JP2022545226A (ja) 2022-10-26
US20220348635A1 (en) 2022-11-03
JP2025004243A (ja) 2025-01-14
AU2026205301A1 (en) 2026-07-23
EP4017874A1 (en) 2022-06-29
JP7781052B2 (ja) 2025-12-05

Similar Documents

Publication Publication Date Title
US10538571B2 (en) Compositions and methods for neurological diseases
US20220348635A1 (en) Compositions and methods for neurological diseases
EP3349760A1 (en) Compositions and methods for treating neurological disorders
JP2026082870A (ja) 神経疾患のための組成物および方法
US20250152742A1 (en) Compositions and methods for neurological diseases
US20250163130A1 (en) Ligand gated ion channels and methods of use
BR122025015501A2 (pt) Receptor modificado, polinucleotídeo, vetor, uso dos mesmos, bem como método para expressão de um receptor modificado em um neurônio

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted